The recombinant human (EGF) market is estimated to be valued at US$ 12246.47 Mn in 2023 and is expected to exhibit a CAGR of 9.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

The recombinant human (EGF) market is estimated to be valued at US$ 12246.47 Mn in 2023 and is expected to exhibit a CAGR of 9.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Recombinant human epidermal growth factor (EGF) is a protein that plays an important role in cell growth, proliferation, and differentiation. It is widely used in cell culture applications to promote cell growth and differentiation. It allows sensitive cell types to survive without the presence of serum or feeder cells. The need for recombinant human EGF from biopharmaceutical companies for use in cell culture media is driving the market growth.

Market key trends:

One of the key trends contributing to the growth of Global Recombinant Human EGF Market Size is the increasing demand from biopharmaceutical companies. Biopharmaceutical industry relies on cell culture systems for manufacturing biologics and vaccines. Recombinant human EGF is an important growth factor added to cell culture media systems used in bioproduction. It promotes growth and survival of various mammalian cell lines used in biomanufacturing. The robust growth of biopharmaceutical industry and increasing demand for monoclonal antibodies and other cellular therapies is fueling the demand for recombinant human EGF protein. The protein is also useful for basic research in cell signaling, angiogenesis and cancer research, further supporting market growth over the forecast period.

Porter's Analysis

Threat of new entrants: The presence of established players with strong brand recognition and distribution networks pose significant entry barriers for new players.

Bargaining power of buyers: Due to availability of substitute products, buyers have moderate bargaining power.

Bargaining power of suppliers: Suppliers have low bargaining power due to presence of several suppliers in the market offering similar raw materials.

Threat of new substitutes: Threat of substitutes is low as there aren't close substitutes for recombinant human EGF.

Competitive rivalry: High due to presence of numerous established and emerging players competing on basis of product quality, price and innovation.

SWOT Analysis

Strength: Wide applications in cell culture media, established distribution networks of key players, high demand from biopharmaceutical companies.

Weakness: Significant R&D investments required, stringent regulatory norms.

Opportunity: Growth in biotechnology and pharmaceutical industries, rising per capita healthcare expenditure.

Threats: Threat from cheaper substitutes, reimbursement issues.


Key Takeaways

The global recombinant human EGF market is expected to witness high growth at a CAGR of 9.3% over the forecast period due to increasing R&D investments in cell-based research. The US market currently dominates due to presence of leading biopharma companies and availability of funds for research. The Asia Pacific region is expected to grow at the fastest pace owing to rising biotechnology industry, increasing healthcare expenditure and presence of emerging economies.

Key players operating in the recombinant human EGF market are Thermo Fisher Scientific, FUJIFILM Irvine Scientific, Inc., ScienCell Research Laboratories, R&D Systems, Abcam PLC, Cell Sciences, Inc., Eurofins DiscoverX, PeproTech, Inc., RayBiotech, Inc., Prospec-Tany TechnoGene Ltd., Miltenyi Biotec, Tonbo Biosciences, BioLegend, Inc., EnQuire BioReagents, STEMCELL Technologies Inc., Cell Guidance Systems Ltd., Creative BioMart, Sino Biological Inc., and BioVision, Inc.

Read Our More Blogs : https://www.dailyprbulletin.com/recombinant-human-egf-market-forecast-outlook-trend-2023-2030/